Multiple Myeloma

An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.

Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.

Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.

Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.

Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.

Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.

C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.

Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.

Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.

C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.

The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.

Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.

Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.

A comprehensive discussion on managing neurotoxicity associated with bispecific antibodies in multiple myeloma.

A panel of experts on multiple myeloma offer insights on the case of a 57-year-old with relapsed/refractory MM treated with an FcRH5 bispecific antibody who develops peripheral neuropathy.

Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.

A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.

Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.

Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.

Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.

Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the benefits obtained when patients have access to a full team of diverse caregivers rather than just a single physician.